The biopharmaceutical firm raises $700M through an expanded equity offering priced at $71 per share.
Cytokinetics completed an upsized equity offering, raising $700M by selling shares at $71 each. The move expands the company’s capital base amid ongoing drug development and operational needs.
The offering was priced at a discount to recent trading levels, reflecting typical market dynamics for large placements. Prior to the raise, the company had not conducted a public equity sale of this scale in over a year.
Shares may face near-term pressure due to dilution, though proceeds could strengthen the balance sheet for pipeline advancement.